Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI

Publication

Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI

Journal Paper/Review - Nov 11, 2019

Weikert Thomas, Maas Ole, Haas Tanja, Klarhöfer Markus, Bremerich Jens, Forrer Flavio, Sauter Alexander Walter, Sommer Gregor

Citation

Weikert T, Maas O, Haas T, Klarhöfer M, Bremerich J, Forrer F, Sauter A, Sommer G. Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. Contrast Media Mol Imaging 2019; 2019:1517208.

Type

Journal Paper/Review (English)

Journal

Contrast Media Mol Imaging 2019; 2019

Publication Date

Nov 11, 2019

Issn Electronic

1555-4317

Pages

1517208

Brief description/objective

The purpose of this study was to determine if parameters derived from diffusion-weighted (DW-) and dynamic contrast-enhanced (DCE-) magnetic resonance imaging (MRI) can help to assess early response to peptide receptor radionuclide therapy (PRRT) with Y-DOTATOC in neuroendocrine hepatic metastases (NET-HM). Twenty patients (10 male; 10 female; mean age: 59.2 years) with NET-HM were prospectively enrolled in this single-center imaging study. DW-MRI and DCE-MRI studies were performed just before and 48 hours after therapy with Y-DOTATOC. Abdominal SPECT/CT was performed 24 hours after therapy. This MRI imaging and therapy session was repeated after a mean interval of 10 weeks. Up to four lesions per patient were evaluated. Response to therapy was evaluated using metastasis sizes at the first and second therapy session as standard for comparison (regressive, stable, and progressive). DW-MRI analysis included the apparent diffusion coefficient (ADC) and parameters related to intravoxel incoherent motion (IVIM), namely, diffusion (), perfusion fraction () and pseudo-diffusion ( ). DCE-MRI analysis comprised K, and . For statistical analysis of group differences, one-way analysis of variance (ANOVA) and appropriate post hoc testing was performed. A total of 51 lesions were evaluated. Seven of 51 lesions (14%) showed size progression, 18/51 (35%) regression, and 26/51 (51%) remained stable. The lesion-to-spleen uptake ratio in SPECT showed a decrease between the two treatment sessions that was significantly stronger in regressive lesions compared with stable ( = 0.013) and progressive lesions ( = 0.021). ANOVA showed significant differences in mean ADC after 48 h ( = 0.026), with higher ADC values for regressive lesions. Regarding IVIM, highest values for at baseline were seen in regressive lesions ( = 0.023). In DCE-MRI, a statistically significant increase in after 10 weeks ( = 0.046) was found in regressive lesions. No differences were observed for the transfer constants K and . Diffusion restriction quantified as ADC was able to differentiate regressive from progressive NET-HMs as early as 48 hours after PRRT. DW-MRI therefore may complement scintigraphy/SPECT for early assessment of response to PRRT. Assessment of perfusion parameters using IVIM and DCE-MRI did not show an additional benefit.